KMT5A抗体—艾普蒂 新品

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using KMT5A mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using KMT5A mouse mAb (green) and negative control (red).    

  
  

The KMT5A antibody is a crucial tool in studying the epigenetic regulator KMT5A (also known as PR/SET Domain 7 or PRDM7), a histone methyltransferase that catalyzes mono-methylation of histone H4 at lysine 20 (H4K20me1). This post-translational modification plays a vital role in chromatin organization, DNA repair, and transcriptional regulation. KMT5A is involved in diverse cellular processes, including cell cycle progression, genomic stability, and differentiation. Dysregulation of KMT5A has been linked to cancers, developmental disorders, and neurological diseases, making it a focus of biomedical research.

The KMT5A antibody is widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to detect protein expression, localization, and interaction partners. Its specificity is validated through knockout cell lines or siRNA-mediated knockdown to ensure accurate targeting. Researchers employ this antibody to explore KMT5A's role in tumorigenesis, particularly its overexpression in cancers such as breast, prostate, and lung cancer, where it may drive proliferation and metastasis. Additionally, it aids in studying KMT5A's involvement in neurological conditions like Alzheimer’s disease, linked to aberrant histone methylation.

As epigenetic therapies gain traction, the KMT5A antibody serves as a key reagent for screening potential inhibitors and understanding mechanisms of KMT5A-related pathologies. Its application extends to basic research on chromatin dynamics and translational studies aiming to develop targeted therapies.